Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

NCT06222437 · Withdrawn

Last updated 2026-05-28

This clinical trial is testing whether semaglutide, a medication, can help manage polycystic ovary syndrome (PCOS) in women by adjusting the dose based on weekly needs.

Status Withdrawn Stopped before any participant enrolled.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Who can join Ages 18–45 · female only

Timeline Started 2026-02 · est. completion 2027-02

What this study is testing ClinicalTrials.gov NCT06222437 ↗

Description as written by the study sponsor.

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Treatments tested

Semaglutide Drug

effectiveness of semaglutide in PCOS

Main thing measured	Number of appropriate weekly dose
Sponsor	Methodist Health System
Conditions studied	Polycystic Ovary Syndrome
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06222437 ↗